|
| 38048045 | Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. | Clin Cancer Res | 2024 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 32968823 | Musculoskeletal Outside Interpretation (MOI-RADS): an automated quality assurance tool to prospectively track discrepancies in second-opinion interpretations in musculoskeletal imaging. | Skeletal Radiology | 2021 |
| 33630091 | Radiogenomics identifying important biological pathways in gliomas. | Neuro-Oncology | 2021 |
| 33664965 | Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. | Neuro-Oncology Practice | 2021 |
| 33112953 | Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. | Neuro Oncol | 2020 |
| 32064507 | Real world use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas. | Neuro-Oncology | 2020 |
| 32642706 | Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. | Neurooncol Adv | 2020 |
| 32923886 | Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent Glioblastoma. | JCO Precis Oncol | 2020 |
| 32909947 | Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. | Elife | 2020 |
| 33067267 | A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. | Cancer Res | 2020 |
| 31197238 | Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. | Sci Rep | 2019 |
| 31727977 | Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. | Sci Rep | 2019 |
| 30397180 | Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. | Clin Cancer Res | 2019 |
| 30131387 | Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. | Clin Cancer Res | 2019 |
| 30565056 | There is an exception to every rule-T2-FLAIR mismatch sign in gliomas. | Neuroradiology | 2019 |
| 31236646 | Assessing the Need for Preprocedural Laboratory Tests and Stopping Non-steroidal Anti-inflammatory Drugs/Aspirin in Patients Undergoing Percutaneous Bone and Soft Tissue Biopsies. | | 2019 |
| 31140557 | Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. | Neuro Oncol | 2019 |
| 31036078 | PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. | Acta Neuropathol Commun | 2019 |
| 31134296 | MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas. | Neuroradiology | 2019 |
| 30975663 | PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. | Clin Cancer Res | 2019 |
| 31456142 | Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. | J Neurooncol | 2019 |
| 30952114 | First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. | Journal of Neurosurgery: Pediatrics | 2019 |
| 29405952 | State of the Art Treatment and Surveillance Imaging of Glioblastomas. | Seminars in Roentgenology | 2018 |
| 30459364 | Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. | Sci Rep | 2018 |
| 29862413 | Quantitative sodium imaging and gliomas: a feasibility study. | Neuroradiology | 2018 |
| 30190259 | Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas. | | 2018 |
| 30082399 | Genotype-targeted local therapy of glioma. | Proc Natl Acad Sci U S A | 2018 |
| 29099956 | Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. | Neuro Oncol | 2018 |
| 29662077 | Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. | Nat Commun | 2018 |
| 27853960 | Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. | J Neurooncol | 2017 |
| 28767654 | Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. | PLoS One | 2017 |
| 28625978 | The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated Cytotoxicity. | Cancer Res | 2017 |
| 28801914 | Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. | Int J Cancer | 2017 |
| 28410478 | Non-contrast MRI diagnosis of adhesive capsulitis of the shoulder. | Clin Imaging | 2017 |
| 28751449 | T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. | Clin Cancer Res | 2017 |
| 28749246 | Identification of more potent imipridones, a new class of anti-cancer agents. | Cell Cycle | 2017 |
| 29872714 | Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. | NPJ Precis Oncol | 2017 |
| 29091765 | Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. | Cell Rep | 2017 |
| 29074213 | Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma. | Journal of Thoracic Oncology | 2017 |
| 29202103 | Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. | NPJ Precis Oncol | 2017 |
| 29108308 | A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. | Oncotarget | 2017 |
| 27775701 | GPR133 (ADGRD1), an adhesion G-protein-coupled receptor, is necessary for glioblastoma growth. | Oncogenesis | 2016 |
| 26845119 | Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. | J Thorac Oncol | 2016 |
| 27382115 | Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. | Neuro Oncol | 2016 |
| 26834160 | Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. | Oncologist | 2016 |
| 27279154 | Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. | J Clin Neurosci | 2016 |
| 27000488 | A 34-Year-Old Male with An Intracranial Mass. | Brain Pathology | 2016 |
| 27076630 | Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. | Clin Cancer Res | 2016 |
| 26534967 | Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. | Clin Cancer Res | 2016 |